Curated News
By: NewsRamp Editorial Staff
September 18, 2025
Viromed Gains ISO 13485 Certification, Launches ViroCAP® Devices in October
TLDR
- Viromed Medical AG gains a competitive edge by independently certifying and marketing ViroCAP devices, accelerating market entry and revenue growth.
- Viromed achieved ISO 13485 certification, establishing a quality management system that enables self-approval of class-I-risk medical devices like ViroCAP.
- Viromed's ViroCAP devices use cold plasma technology for contact-free treatment of skin diseases, improving patient care and medical outcomes.
- At 160 grams, ViroCAP is the world's lightest mobile cold plasma device, launching in October 2025 for dermatology and veterinary use.
Impact - Why it Matters
This development matters because it introduces innovative, non-invasive medical technology that could transform treatment for skin diseases and wounds, offering patients safer, contact-free options with reduced infection risks. For the healthcare industry, Viromed's certification and product launch signal advancements in cold plasma applications, potentially leading to more efficient and accessible treatments. Investors and stakeholders may benefit from the company's growth potential and competitive edge in emerging medical markets.
Summary
Viromed Medical AG, a German medical technology company and pioneer in cold plasma technology, has achieved a significant milestone by receiving ISO 13485 certification, officially establishing itself as a medical device manufacturer. This certification, obtained through NEWMEDIAWIRE, enables Viromed to independently approve and market its innovative ViroCAP® product family, with sales and deliveries set to begin in October 2025. CEO Uwe Perbandt emphasized that this transition from developer to approved manufacturer unlocks new revenue potential and provides a competitive advantage, accelerating the company's growth and market expansion.
The ISO 13485 certification is a critical requirement under Europe's Medical Device Regulation (MDR), validating that Viromed has implemented a robust quality management system meeting international standards. This achievement lays the foundation for the rapid market launch of ViroCAP® devices, including ViroCAP® derma for dermatology, ViroCAP® med for wound treatment, and ViroCAP® vet for veterinary use. Weighing just 160 grams, ViroCAP® is the world's lightest mobile cold plasma device, featuring contact-free treatment technology that eliminates direct skin or wound contact, enhancing safety and convenience.
With the ability to independently certify class-I-risk products, Viromed gains flexibility and speed in entering attractive growth markets in dermatology and clinical environments. The company, listed on the stock exchange since 2022 and operating via its subsidiary Viromed Medical GmbH, aims to advance cold plasma technology in medicine and realize substantial growth potential. For more details, readers can visit www.newmediawire.com to view the original release.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Viromed Gains ISO 13485 Certification, Launches ViroCAP® Devices in October
